The TIDOS project is an observational cohort study of short and long term infectious disease outcomes following a deployment-related traumatic injury. TIDOS cohort eligibility criteria include the following: active duty personnel or DoD beneficiary, ≥ 18 years of age, wounded or injured during deployment requiring return via Level IV at Landstuhl Regional Medical Center (LRMC), Landstuhl, Germany to a participating DoD hospital in the U.S., and providing informed consent or surrogate consent through a legally authorized representative. Participating Level V clinical sites include the National Naval Medical Center (NNMC), Bethesda, MD, Brooke Army Medical Center (BAMC), San Antonio, TX, and Walter Reed Army Medical Center (WRAMC), Washington DC. Consenting patients are enrolled in the study prior to discharge from one of the participating Level V hospitals. Participants are contacted periodically at 1, 3, 6, 12, 18, 24 months and then yearly for 5 years after discharge. Follow-up methods include subject interviews, web-based questionnaires, and query of DoD and Department of Veterans Affairs electronic healthcare databases.
Patient trauma history, injury severity scoring, and surgical management is obtained through selected data elements retrieved from the DoD Joint Theater Trauma Registry (JTTR).5 (link) The JTTR was established by the Assistant Secretary of Defense for Health Affairs as a means to provide an effective performance improvement tool to assess combat casualty care epidemiology, treatment, and outcome. An infectious diseases (ID) module to augment the JTTR was developed to capture infection-specific data throughout levels of care at participating hospitals. This ID-specific information includes diagnoses, treatments, and outcomes of bloodstream infections (BSI), clinical sepsis, bone and joint infections, skin and soft tissue infections (SSTI), central nervous system infections (CNS), intra-thoracic/pulmonary infections, and intra-abdominal infection. The JTTR/ID module captures data on all active duty military trauma patients admitted to Level IV and selected Level V facilities. A comprehensive assessment of the overall population and the representativeness of the TIDOS cohort were performed by analyzing de-identified JTTR/ID module data from non-enrolled trauma patients admitted through Level IV during the period. The study is approved by the institutional review boards of the Uniformed Services University of the Health Sciences and the St. Louis Veterans Administration Medical Center (VAMC).
This report includes subjects admitted to Level IV during the first three months of the study (June 1 – August 31, 2009) along with subject experience through Level V hospitalization (for those admitted to participating Level V sites) and up to 6-months of follow-up post Level V discharge (for those consenting to follow-up).
Patient trauma history, injury severity scoring, and surgical management is obtained through selected data elements retrieved from the DoD Joint Theater Trauma Registry (JTTR).5 (link) The JTTR was established by the Assistant Secretary of Defense for Health Affairs as a means to provide an effective performance improvement tool to assess combat casualty care epidemiology, treatment, and outcome. An infectious diseases (ID) module to augment the JTTR was developed to capture infection-specific data throughout levels of care at participating hospitals. This ID-specific information includes diagnoses, treatments, and outcomes of bloodstream infections (BSI), clinical sepsis, bone and joint infections, skin and soft tissue infections (SSTI), central nervous system infections (CNS), intra-thoracic/pulmonary infections, and intra-abdominal infection. The JTTR/ID module captures data on all active duty military trauma patients admitted to Level IV and selected Level V facilities. A comprehensive assessment of the overall population and the representativeness of the TIDOS cohort were performed by analyzing de-identified JTTR/ID module data from non-enrolled trauma patients admitted through Level IV during the period. The study is approved by the institutional review boards of the Uniformed Services University of the Health Sciences and the St. Louis Veterans Administration Medical Center (VAMC).
This report includes subjects admitted to Level IV during the first three months of the study (June 1 – August 31, 2009) along with subject experience through Level V hospitalization (for those admitted to participating Level V sites) and up to 6-months of follow-up post Level V discharge (for those consenting to follow-up).
